Breaking News

Mylan To Acquire Pfizer Respiratory Platform

Gains rights to Pfizer’s dry-powder delivery platform

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Mylan has entered into an agreement for the exclusive worldwide rights to develop, manufacture and commercialize Pfizer’s generic equivalent to GlaxoSmithKline’s Advair Diskus and Seretide Diskus, using Pfizer’s dry powder inhaler delivery platform. Both drugs are inhaled fixed-dose combinations of Fluticasone Propionate and Salmeterol delivered via a dry powder inhaler for the treatment of asthma and COPD. Mylan will also gain rights to Pfizer’s dry-powder delivery platform to...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters